Publikation

Integrative Modeling Reveals Annexin A2-mediated Epigenetic Control of Mesenchymal Glioblastoma

Wissenschaftlicher Artikel/Review - 18.09.2016

Bereiche
PubMed
DOI

Zitation
Kling T, Carro M, Jörnsten R, Weyerbrock A, Vasilikos I, Dai F, Heiland D, Johansson P, Ó hAilín D, Ferrarese R, Nelander S. Integrative Modeling Reveals Annexin A2-mediated Epigenetic Control of Mesenchymal Glioblastoma. EBioMedicine 2016; 12:72-85.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
EBioMedicine 2016; 12
Veröffentlichungsdatum
18.09.2016
eISSN (Online)
2352-3964
Seiten
72-85
Kurzbeschreibung/Zielsetzung

Glioblastomas are characterized by transcriptionally distinct subtypes, but despite possible clinical relevance, their regulation remains poorly understood. The commonly used molecular classification systems for GBM all identify a subtype with high expression of mesenchymal marker transcripts, strongly associated with invasive growth. We used a comprehensive data-driven network modeling technique (augmented sparse inverse covariance selection, aSICS) to define separate genomic, epigenetic, and transcriptional regulators of glioblastoma subtypes. Our model identified Annexin A2 (ANXA2) as a novel methylation-controlled positive regulator of the mesenchymal subtype. Subsequent evaluation in two independent cohorts established ANXA2 expression as a prognostic factor that is dependent on ANXA2 promoter methylation. ANXA2 knockdown in primary glioblastoma stem cell-like cultures suppressed known mesenchymal master regulators, and abrogated cell proliferation and invasion. Our results place ANXA2 at the apex of a regulatory cascade that determines glioblastoma mesenchymal transformation and validate aSICS as a general methodology to uncover regulators of cancer subtypes.